Post-SARS-CoV-2 Acute Telogen Effluvium: An Expected Complication
Paola Monari, Giulio Gualdi, Giorgio Bettoni, Raffaella Costa, G Ragni, Francesca Zani, G. Bianchi, Silvia Casella, E. Casella, Massimo P. Crippa, Piergiacomo Calzavara‐Pinton, Marta Di Nicola, Annamaria Porreca, Paolo Amerio, Pierangelo Guizzi
Abstract
Post-SARS-CoV-2 telogen effluvium has been described in case reports of COVID-19 patients. We evaluated the prevalence of post-SARS-CoV-2 telogen effluvium in patients from a single medical center, exploring any causal links with the infection. Our hospital-based, cross-sectional study was conducted with patient participants discharged with a diagnosis of SARS-CoV-2 pneumonia from 1 March to 4 April 2020. All patients were evaluated by the same senior dermatologist; a clinical/dermatoscopic evaluation was performed. Alopecia was assessed in 31.3% of patients, with a significant difference in sex (females 73%, males 26.7%). The average time detected from the onset of the first symptoms to alopecia was 68.43 days. Overall, there were no significant associations between alopecia and COVID-19-related features (length of hospitalization, virologic positivity, or duration of fever), treatment characteristics, or laboratory findings. In this paper, we report that post-infection acute telogen effluvium occurs in a significant number of COVID-19 patients. The burden of this condition may impair the quality of life, with a significant impact on individuals.